Abstract

Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags

Author(s): Nalenz Heiko, Köpf Ellen, Dietel Elke

Issue: Sep/Oct 2018 - Volume 22, Number 5

Page(s): 417-423

Download in electronic PDF format for $75
  • Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 1
  • Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 2
  • Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 3
  • Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 4
  • Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 5
  • Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 6
  • Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 7

Abstract

Herceptin is a humanized monoclonal antibody that selectively binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Herceptin has an important role in the treatment of HER2-positive breast cancer when used in the neoadjuvant, adjuvant, and metastatic settings, and in the treatment of HER2-positive metastatic gastric cancer, and gastroesophageal junction adenocarcinoma. Prior to intravenous infusion, Herceptin must be reconstituted with sterile water for injection and then diluted in intravenous bags with normal saline. The objective of this study was to test the in-use physicochemical stability of the Herceptin drug product after dilution in 0.9% sodium chloride in commercial polyvinylchloride, and polyolefin/ polyethylene/polypropylene infusion bags over the course of a 7-day storage at 2°C to 8°C followed by 24 hours of storage at 30°C with ambient light exposure. Three batches of Herceptin were reconstituted to yield a 21-mg/mL solution that was stored for 48 hours at 2°C to 8°C prior to dilution with 0.9% sodium chloride to create low (0.24-mg/mL) and high (3.84-mg/mL) concentration solutions that were then tested in simulated infusions with a polyvinylchloride or polyolefin/polyethylene/polypropylene infusion bag. Samples for analysis were obtained immediately after dilution of the reconstituted solution (T0), after 7 days of storage at 5°C (T7), after 1 further day of storage at 30°C (T7+1), and after administration through intravenous tubing (Tend). Control samples were obtained from bags containing only 0.9% sodium chloride at each time point. For experiments with both infusion bags, all samples were practically free from particles, were colorless, and had low numbers of subvisible particles with no differences between control and experimental samples. No change in turbidity was detected between T0 and Tend for low and high-concentration samples for each batch. The pH values remained consistent between T0 and T7+1, and osmolality values were consistent across low-concentration and high-concentration samples. Protein content, size, and potency remained consistent throughout storage and simulated infusion. In conclusion, Herceptin remains physicochemically stable for 7 days when stored at 2°C to 8°C, followed by an additional 24 hours at 30°C when diluted in 0.9% sodium chloride and stored in commercially available polyvinylchloride or polyolefin/polyethylene/polypropylene infusion bags.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2018
Pg. 417-423
May/Jun 2021
Pg. 246-257
Jul/Aug 2000
Pg. 264-272
Author(s): Davidson Gigi S
Jul/Aug 2002
Pg. 250-254
Author(s): Zava David T
Nov/Dec 2022
Pg. 446-466
Author(s): Allen Loyd V Jr
Jul/Aug 2000
Pg. 257-260
Author(s): Maddox Suzan
Jan/Feb 1998
Pg. 21-23
May/Jun 2005
Pg. 195-198
Author(s): Davidson Gigi S
Sep/Oct 2015
Pg. 432-436
Jul/Aug 2022
Pg. 336-341
Sep/Oct 2017
Pg. 436-439
Mar/Apr 2010
Pg. 100-104
Author(s): Biundo Bruce
Jan/Feb 2013
Pg. 74-85
View Sample
May/Jun 2007
Pg. 212-218
Author(s): McNulty Jack P
Sep/Oct 2007
Pg. 426-432
Jan/Feb 2008
Pg. 16-27
Author(s): Williams LaVonn A
Jan/Feb 2008
Pg. 62
Author(s): Stockton Shelly J
Jul/Aug 2011
Pg. 290-300
Sep/Oct 2010
Pg. 366-369
Author(s): Briggs Valerie
Sep/Oct 2010
Pg. 428
Author(s): Allen Loyd V Jr